FDA panel to review once-rejected Acadia drug for psychosis

After receiving a rejection last year, Acadia said Wednesday that the Food and Drug Administration agreed to review its resubmitted application to expand use of the drug Nuplazid. The agency expects to decide on approval by Aug. 4, but will convene a group of outside advisers to weigh in.